MyRisk is expected to continue its strong ... and we've been pretty open about those things. The strength of Myriad Genetics, though, is the diversity of our portfolio and the many different ...

HighlightsThird quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on ...

Myriad Genetics and agency partner S50 Health educated OBGYNs and their patients in a campaign called “Getting Ahead of ...

TD Cowen lowered the firm’s price target on Myriad Genetics (MYGN) to $20 from $30 and keeps a Hold rating on the shares. The firm said a focal point tonight was assessing UnitedHealth’s (UNH ...

that allows physicians to order Myriad Genetics’ MyRisk Hereditary Cancer Test and view the results of the test directly in Flatiron’s cloud-based Electronic Medical Record (EMR) platform ...

SALT LAKE CITY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its third quarter ...

Myriad Genetics generated approximately $10 million and $40 million of GeneSight revenue from UNH's commercial population in the third quarter and trailing twelve month period ended September 30, ...